{"classes":[{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient events observed","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA: Not estimable due to insufficient events observed","groupId":"OG001","lowerLimit":"64.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Duration of CCyR was defined as the time between date of first documented CCyR and the earliest date of loss of CCyR, progression to AP/BC, or CML-related death for participants in the Cytogenetic Responder Set. The time was censored at the last cytogenetic assessment date on treatment for participants for whom none of the events was reported or last PCR evaluation on treatment indicating MMR.","dispersionType":"Full Range","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"MEDIAN","populationDescription":"CCyR responder set was a subset of FAS and included patients who did not have CCyR at baseline and achieved CCyR at any time on randomized treatment. FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"144 weeks","title":"Duration of Complete Cytogenetic Response (CCyR)","type":"SECONDARY","unitOfMeasure":"Weeks"}